| Primary |
| General Anaesthesia |
40.0% |
| Induction Of Anaesthesia |
40.0% |
| Analgesic Therapy |
20.0% |
|
| Anaphylactic Shock |
50.0% |
| Erythema |
50.0% |
|
| Secondary |
| Anaesthesia |
26.5% |
| Induction Of Anaesthesia |
25.7% |
| Drug Use For Unknown Indication |
10.7% |
| General Anaesthesia |
10.3% |
| Product Used For Unknown Indication |
8.1% |
| Endotracheal Intubation |
1.8% |
| Hypertension |
1.8% |
| Antibiotic Prophylaxis |
1.6% |
| Gastrooesophageal Reflux Disease |
1.6% |
| Premedication |
1.6% |
| Preoperative Care |
1.6% |
| Abdominal Pain |
1.4% |
| Pain |
1.4% |
| Perioperative Analgesia |
1.2% |
| Anxiety |
1.0% |
| Diarrhoea |
0.8% |
| Influenza |
0.8% |
| Local Anaesthesia |
0.8% |
| Sedation |
0.8% |
| Bronchopneumonia |
0.6% |
|
| Anaphylactic Shock |
43.1% |
| Shock |
9.7% |
| Hypotension |
6.3% |
| Rash |
5.6% |
| Tachycardia |
4.9% |
| Bronchospasm |
4.2% |
| Circulatory Collapse |
4.2% |
| Generalised Erythema |
4.2% |
| Tryptase Increased |
2.8% |
| Cardiac Arrest |
2.1% |
| Ventricular Fibrillation |
2.1% |
| Blood Pressure Decreased |
1.4% |
| Hypersensitivity |
1.4% |
| Renal Failure |
1.4% |
| Sinus Tachycardia |
1.4% |
| Urticaria |
1.4% |
| Ventricular Arrhythmia |
1.4% |
| Ventricular Tachycardia |
1.4% |
| Anaphylactoid Shock |
0.7% |
| Angioedema |
0.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
12.1% |
| Prophylaxis |
10.5% |
| Anaesthesia |
9.7% |
| Diverticular Perforation |
8.9% |
| Agitation |
6.5% |
| Drug Use For Unknown Indication |
6.5% |
| Induction Of Anaesthesia |
6.5% |
| Spinal Anaesthesia |
6.5% |
| Depression |
4.0% |
| Epilepsy |
3.2% |
| General Anaesthesia |
3.2% |
| Infection Prophylaxis |
3.2% |
| Pneumonia |
3.2% |
| Psychotic Disorder |
3.2% |
| Sedation |
3.2% |
| Third Stage Postpartum Haemorrhage |
3.2% |
| Abdominal Infection |
2.4% |
| Gastrooesophageal Reflux Disease |
1.6% |
| Postpartum Haemorrhage |
1.6% |
| Antibiotic Prophylaxis |
0.8% |
|
| Skin Test Positive |
12.5% |
| Gamma-glutamyltransferase Increased |
8.3% |
| Toxic Epidermal Necrolysis |
8.3% |
| Anaesthetic Complication |
4.2% |
| Bronchospasm |
4.2% |
| Cardiac Arrest |
4.2% |
| Circulatory Collapse |
4.2% |
| Generalised Erythema |
4.2% |
| Myoclonus |
4.2% |
| Pharmaceutical Product Complaint |
4.2% |
| Pneumonia Staphylococcal |
4.2% |
| Pulmonary Congestion |
4.2% |
| Pyrexia |
4.2% |
| Rash Pustular |
4.2% |
| Septic Shock |
4.2% |
| Stenotrophomonas Infection |
4.2% |
| Tachycardia |
4.2% |
| Tongue Oedema |
4.2% |
| Urinary Tract Infection |
4.2% |
| Ventricular Arrhythmia |
4.2% |
|
